Novaremed AG

What Novaremed AG does

Novaremed AG is a privately held, clinical-stage Swiss biopharmaceutical company headquartered in Basel, founded in 2017 as the parent holding company for Novaremed Ltd (Israel, founded 2008) and, since September 2021, Metys Pharmaceuticals AG. The company develops orally active, non-opioid small-molecule therapies for chronic neuropathic pain, with a pipeline led by nispomeben (NRD.E1 / NRD135S.E1) — a Lyn kinase phosphorylation modulator targeting painful diabetic peripheral neuropathy (PDPN) — and supplemented by MP-101 (a non-racemic dimiracetam mixture and glutamate signaling modulator in Phase 2 for chemotherapy-induced peripheral neuropathy, or CIPN) and the preclinical MP-103.

The lead candidate nispomeben has completed four Phase 1 studies and a Phase 2a proof-of-concept in 88 PDPN patients showing clinically relevant, dose-related pain reduction and favorable tolerability, and is now being evaluated in an NIH-sponsored, HEAL Initiative-funded Phase 2b trial (EN21-01, 127 patients enrolled, topline expected November 2025). FDA Fast Track Designation was granted in December 2020, and nispomeben is the only oral agent included in the EPPIC-Net master protocol. The company is exploring life-cycle management into additional pain indications.

Novaremed's commercial strategy is asset-light: it out-licenses regional rights (e.g., the July 2022 NeuroFront deal covering Greater China and Singapore, valued at over USD 130 million in potential milestones plus royalties) and outsources late-stage US clinical execution to NIH/EPPIC-Net. There are no commercialized products and therefore no product revenue. To date the company has raised approximately CHF 23.5 million in disclosed equity and secured a US $50 million capital commitment facility from GEM Global Yield LLC SCS conditional on a future public listing. With only 1–10 employees and revenues effectively nil, value creation is gated entirely on clinical and regulatory milestones rather than top-line growth.

Name

Novaremed AG

Legal name

Novaremed AG

Website

https://novaremed.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Novaremed AG is a privately held, clinical-stage Swiss biopharmaceutical company developing non-opioid small-molecule therapies for chronic neuropathic pain, with lead candidate nispomeben in Phase 2b for painful diabetic peripheral neuropathy and MP-101 in Phase 2 for chemotherapy-induced peripheral neuropathy.

Ownership category

akta.pro rank

Product category

Non-opioid pain therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Non-opioid pain therapeutics
• Neuropathic pain treatment
• Diabetic peripheral neuropathy
• Chemotherapy-induced neuropathy
• Clinical-stage biopharmaceuticals

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Drug Development and Commercialization: Novaremed is developing a pipeline of non-opioid chronic pain therapies. Revenue would be generated through eventual product sales if clinical trials succeed and regulatory approvals are obtained.
2. Licensing and Milestone Payments: Novaremed receives option and exercise fees, development, regulatory and sales milestone payments, and royalties on net sales from licensing partners such as NeuroFront for Greater China and Singapore (valued at over USD 130 million plus royalties).
3. Capital Commitment Facility: GEM Global Yield LLC SCS committed to provide up to US $50 million share subscription facility for 36 months following public listing, giving Novaremed flexibility to drawdown capital as needed.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Novaremed AG is a clinical-stage biopharmaceutical company developing non-opioid small molecule therapies for chronic neuropathic pain. Its pipeline targets painful diabetic peripheral neuropathy (PDPN) with lead candidate nispomeben (NRD.E1) and chemotherapy-induced peripheral neuropathy (CIPN) with MP-101 (Phase 2) and MP-103 (preclinical). The company intends to commercialize through out-licensing partnerships and co-development arrangements.

Product overview

Novaremed AG is a clinical-stage biopharmaceutical company developing a pipeline of non-opioid treatments for chronic pain management. The company's portfolio consists of three development candidates: nispomeben (NRD.E1/NRD135S.E1) as the lead product for painful diabetic peripheral neuropathy (PDPN), MP-101 (Phase 2) for chemotherapy-induced peripheral neuropathy (CIPN) prevention, and MP-103 (preclinical) targeting CIPN and other peripheral neuropathy indications. Nispomeben operates as a Lyn kinase modulator with a novel mechanism of action distinct from opioids, while MP-101 and MP-103 work through glutamate signaling modulation. The company operates through wholly-owned subsidiaries Novaremed Ltd (Israel) and Metys Pharmaceuticals AG (Switzerland), headquartered in Basel, Switzerland.

Differentiator

Problem solved

Functional benefit

Products and services

• Nispomeben (NRD.E1 / NRD135S.E1) Lead product candidate: an orally active, non-opioid small molecule with a novel Lyn kinase modulatory mechanism that decreases phosphorylation of Y-507 of Lyn kinase, reducing P2X4 purinergic receptor upregulation in the central nervous system. Granted FDA Fast Track Designation in December 2020. In clinical development for painful diabetic peripheral neuropathy (PDPN).
• MP-101 Phase 2 clinical candidate that is an orally available modulator of glutamate signaling intended to address peripheral neuropathies. A patented non-racemic mixture of dimiracetam enantiomers (3 parts R-dimiracetam and 1 part S-dimiracetam) being developed for prevention of chemotherapy-induced peripheral neuropathy (CIPN). Patent protection until 2038.
• MP-103

Quantifiable outcome

• Phase 2a showed clinically relevant placebo-corrected pain reductions at 40 and 150 mg/day doses (0.82 NRS points, p=0.034)
• +2 more outcomes

Segments2 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• NeuroFront Therapeutics (Hong Kong) LimitedcoreTechnology or Integration · 21 July 2022Novaremed granted NeuroFront an exclusive option to obtain exclusive development, commercialization and manufacturing rights to NRD.E1 for treatment of painful diabetic peripheral neuropathy and other neuropathic pain indications in Greater China territory (including Mainland China, Hong Kong, Macau, and Taiwan) and Singapore. NeuroFront can exercise its license option at its discretion but no later than upon completion of the Phase 2b trial. Novaremed eligible to receive over USD 130 million in option and exercise fees, development, regulatory and sales milestone payments, plus royalties on net sales.
• NIH HEAL Initiative / EPPIC-NetcoreStrategic or Co-development Partner · 21 December 2021The NIH, through its HEAL Initiative, sponsors and conducts the Phase 2b EN21-01 SERENDIPITY-1 study evaluating NRD.E1 in patients with painful diabetic peripheral neuropathy. EPPIC-Net (Early Phase Pain Investigation Clinical Network) runs the study in the US. Novaremed provides drug supply while NIH funds and executes the trial. Nispomeben was selected as the only oral agent to be included in the EPPIC-Net master protocol.
• Metys Pharmaceuticals AGcoreOthers · 7 September 2021Novaremed acquired Metys Pharmaceuticals AG, including all its development programs, in an all-share transaction. The acquisition expanded Novaremed's pipeline with clinical candidate MP-101 (Phase 2) for chemotherapy-induced peripheral neuropathy and preclinical candidate MP-103. Metys founder Michael Scherz joined as part of the transaction, and Andrew J. Oakley joined Novaremed's Board of Directors.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Lexicon Pharmaceuticals: Lexicon is developing LX9211 (AAK1 inhibitor) for painful diabetic neuropathy with a similar clinical-stage profile to nispomeben, directly comparable in indication, mechanism novelty, and target patient population.
• Cara Therapeutics: Cara Therapeutics develops difelikefalin for neuropathic pruritus and pain, making it a clinical-to-commercial stage peer in the peripheral neuropathic symptom space adjacent to Novaremed's PDPN focus.
• Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pain company with marketed products addressing chronic pain, providing a comparable commercial-stage business model in non-opioid pain therapeutics.
• Vertex Pharmaceuticals: Vertex Pharmaceuticals recently received FDA approval for suzetrigine (Journavx), a non-opioid pain therapeutic — making it the most directly comparable commercial-stage competitor validating the non-opioid pain category Novaremed targets.
• Grünenthal: Grünenthal is a privately-held pain-specialist pharmaceutical company with a portfolio including Qutenza for neuropathic pain, offering a comparable focus on non-opioid and specialty pain therapeutics.

Emerging players

• Aptinyx: Aptinyx develops NMDA receptor modulators (NYX-2925) for neuropathic pain, overlapping with Novaremed's neuropathic pain focus but with a different mechanism and somewhat earlier-stage development.
• Hoba Therapeutics: Hoba Therapeutics is a preclinical-stage biotech developing novel non-opioid pain therapeutics, representing an emerging player addressing similar unmet medical needs in chronic neuropathic pain.
• Vyne Therapeutics: Vyne Therapeutics is an emerging specialty biopharma developing therapies for pain and inflammatory conditions, partially overlapping with Novaremed's chronic non-opioid pain portfolio.

Broad incumbents

• Pfizer: Pfizer's pregabalin (Lyrica) was historically the leading PDPN therapy and remains a benchmark incumbent, making Pfizer a broad incumbent comparable via PDPN market positioning rather than direct competition.
• Eli Lilly: Eli Lilly markets duloxetine (Cymbalta), one of the leading approved PDPN therapies, making it a broad incumbent competitor in the same indication Novaremed is pursuing with nispomeben.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novaremed AG